Molecular Basis for the Selectivity of the Mammalian Bombesin Peptide, Neuromedin B, for Its Receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 1, 2009, Pages 265-276

  González, Nieves ^a   Nakagawa, Tomoo ^a,b   Mantey, Samuel A ^a   Sancho, Veronica ^a   Uehara, Hirotsugu ^a,b   Katsuno, Tatsuro ^a,b   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BOMBESIN DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; NEUROMEDIN B; NEUROMEDIN B RECEPTOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; LOSS OF FUNCTION MUTATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; CRICETINAE; CRICETULUS; EXTRACELLULAR SPACE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUROKININ B; NIH 3T3 CELLS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, BOMBESIN;

EID: 70349332668     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.154245     Document Type: Article

References (44)

1. Akeson M, Sainz E, Mantey SA, Jensen RT, and Battey JF (1997) Identification of four amino acids in the gastrin-releasing peptide receptor that are required for high affinity agonist binding. J Biol Chem 272:17405-17409. (Pubitemid 27311169)
2. Battey JF, Way JM, Corjay MH, Shapira H, Kusano K, Harkins R, Wu JM, Slattery T, Mann E, and Feldman RI (1991) Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc Natl Acad Sci U S A 88:395-399. (Pubitemid 21915471)
3. Benya RV, Fathi Z, Battey JF, and Jensen RT (1993) Serines and threonines in the gastrin-releasing peptide receptor carboxyl terminus mediate internalization. J Biol Chem 268:20285-20290. (Pubitemid 23278934)
4. Benya RV, Fathi Z, Kusui T, Pradhan T, Battey JF, and Jensen RT (1994) Gastrin-releasing peptide receptor-induced internalization, down-regulation, desensitization and growth: possible role for cyclic AMP. Mol Pharmacol 46:235-245. (Pubitemid 24271419)
5. Benya RV, Wada E, Battey JF, Fathi Z, Wang LH, Mantey SA, Coy DH, and Jensen RT (1992) Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharmacol 42:1058-1068. (Pubitemid 23028843)
6. Black SD and Mould DR (1991) Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications. Anal Biochem 193:72-82.
7. Couvineau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P, and Laburthe M (1996) Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J Biol Chem 271:12795-12800. (Pubitemid 26175851)
8. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, and Minna JD (1985) Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316:823-826. (Pubitemid 15003742)
9. Escrieut C, Gigoux V, Archer E, Verrier S, Maigret B, Behrendt R, Moroder L, Bignon E, Silvente-Poirot S, Pradayrol L, et al. (2002) The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process. J Biol Chem 277:7546-7555. (Pubitemid 34953153)
10. Fathi Z, Benya RV, Shapira H, Jensen RT, and Battey JF (1993) The fifth transmembrane segment of the neuromedin B receptor is critical for high affinity neuromedin B binding. J Biol Chem 268:14622-14626. (Pubitemid 23206597)
11. Fong TM, Yu H, and Strader CD (1992) Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. J Biol Chem 267:25668-25671. (Pubitemid 23013958)
12. Gonzalez N, Hocart SJ, Portal-Nuñez S, Mantey SA, Nakagawa T, Zudaire E, Coy DH, and Jensen RT (2008) Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor. J Pharmacol Exp Ther 324:463-474. (Pubitemid 351185848)
13. Greenfeder S, Cheewatrakoolpong B, Billah M, Egan RW, Keene E, Murgolo NJ, and Anthes JC (1999) The neurokinin-1 and neurokinin-2 receptor binding sites of MDL103,392 differ. Bioorg Med Chem 7:2867-2876. (Pubitemid 30105859)
14. Hoare SR, Brown BT, Santos MA, Malany S, Betz SF, and Grigoriadis DE (2006) Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor 1 (CRF1) receptor. Biochem Pharmacol 72:244-255. (Pubitemid 43850430)
15. Holtmann MH, Hadac EM, and Miller LJ (1995) Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors. J Biol Chem 270:14394-14398.
16. Jensen JA, Carroll RE, and Benya RV (2001) The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 22:689-699.
17. Jensen RT, Battey JF, Spindel ER, and Benya RV (2008) International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol Rev 60:1-42.
18. Jensen RT and Moody TW (2006) Bombesin-related peptides and neurotensin: effects on cancer growth/proliferation and cellular signaling in cancer, in Handbook of Biologically active peptides (Kastin AJ ed) pp 429-434, Elsevier, Amsterdam.
19. Kim H (2006) Activity of human dihydrolipoamide dehydrogenase is largely reduced by mutation at isoleucine-51 to alanine. J Biochem Mol Biol 39:223-227.
20. Ladenheim EE, Jensen RT, Mantey SA, and Moran TH (1992) Distinct distributions of two bombesin receptor subtypes in the rat central nervous system. Brain Res 593:168-178.
21. Li H, Hsu P, Sachais BS, Krause JE, Leeman SE, and Boyd ND (1996) Identification of the site in the substance P (NK-1) receptor for modulation of peptide binding by sulfhydryl reagents. J Biol Chem 271:1950-1956. (Pubitemid 26047775)
22. Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, and Maki RA (1997) Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol Endocrinol 11:2048-2053. (Pubitemid 27524887)
23. Mantey SA, Weber HC, Sainz E, Akeson M, Ryan RR, Pradhan TK, Searles RP, Spindel ER, Battey JF, Coy DH, et al. (1997) Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem 272:26062-26071. (Pubitemid 27438937)
24. McCoy JG and Avery DD (1990) Bombesin: potential integrative peptide for feeding and satiety. Peptides 11:595-607.
25. Meng F, Taylor LP, Hoversten MT, Ueda Y, Ardati A, Reinscheid RK, Monsma FJ, Watson SJ, Civelli O, and Akil H (1996) Moving from the orphanin FQ receptor to an opioid receptor using four point mutations. J Biol Chem 271:32016-32020. (Pubitemid 26422228)
26. Moody TW and Merali Z (2004) Bombesin-like peptides and associated receptors within the brain: distribution and behavioral implications. Peptides 25:511-520.
27. Mosebi S, Sayed Y, Burke J, and Dirr HW (2003) Residue 219 impacts on the dynamics of the C-terminal region in glutathione transferase A1-1: implications for stability and catalytic and ligandin functions. Biochemistry (Mosc) 42:15326-15332. (Pubitemid 38031731)
28. Nakagawa T, Hocart SJ, Schumann M, Tapia JA, Mantey SA, Coy DH, Tokita K, Katsuno T, and Jensen RT (2005) Identification of key amino acids in the gastrin-releasing peptide receptor (GRPR) responsible for high affinity binding of gastrin-releasing peptide (GRP). Biochem Pharmacol 69:579-593.
29. Nickolls SA, Cismowski MI, Wang X, Wolff M, Conlon PJ, and Maki RA (2003) Molecular determinants of melanocortin 4 receptor ligand binding and MC4/MC3 receptor selectivity. J Pharmacol Exp Ther 304:1217-1227. (Pubitemid 36254435)
30. Pradhan TK, Katsuno T, Taylor JE, Kim SH, Ryan RR, Mantey SA, Donohue PJ, Weber HC, Sainz E, Battey JF, et al. (1998) Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol 343:275-287. (Pubitemid 28138612)
31. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, and Gugger M (2002) Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-Tyr(6), beta-Ala(11), Phe(13), Nle(14)] bombesin(6-14). Clin Cancer Res 8:1139-1146.
32. Ryan RR, Katsuno T, Mantey SA, Pradhan TK, Weber HC, Coy DH, Battey JF, and Jensen RT (1999) Comparative pharmacology of the nonpeptide neuromedin B antagonist PD 168368. J Pharmacol Exp Ther 290:1202-1211. (Pubitemid 29400262)
33. Sainz E, Akeson M, Mantey SA, Jensen RT, and Battey JF (1998) Four amino acid residues are critical for high affinity binding of neuromedin B to the neuromedin B receptor. J Biol Chem 273:15927-15932. (Pubitemid 28311356)
34. Silvente-Poirot S, Escrieut C, Galès C, Fehrentz JA, Escherich A, Wank SA, Martinez J, Moroder L, Maigret B, Bouisson M, et al. (1999) Evidence for a direct interaction between the penultimate aspartic acid of cholecystokinin and histidine 207, located in the second extracellular loop of the cholecystokinin B receptor. J Biol Chem 274:23191-23197.
35. Silvente-Poirot S, Escrieut C, and Wank SA (1998) Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol Pharmacol 54:364-371. (Pubitemid 28368826)
36. Silvente-Poirot S and Wank SA (1996) A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin. J Biol Chem 271:14698-14706. (Pubitemid 26194945)
37. Spivak CE, Beglan CL, Seidleck BK, Hirshbein LD, Blaschak CJ, Uhl GR, and Surratt CK (1997) Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity. Mol Pharmacol 52:983-992.
38. Sun B, Schally AV, and Halmos G (2000) The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept 90:77-84. (Pubitemid 30331013)
39. Tokita K, Hocart SJ, Coy DH, and Jensen RT (2002) Molecular basis of the selectivity of gastrin-releasing peptide receptor for gastrin-releasing peptide. Mol Pharmacol 61:1435-1443. (Pubitemid 34575754)
40. Tokita K, Hocart SJ, Katsuno T, Mantey SA, Coy DH, and Jensen RT (2001a) Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368. J Biol Chem 276:495-504. (Pubitemid 32050343)
41. Tokita K, Katsuno T, Hocart SJ, Coy DH, Llinares M, Martinez J, and Jensen RT (2001b) Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor. J Biol Chem 276:36652-36663. (Pubitemid 37384279)
42. Tsuda T, Kusui T, Hou W, Benya RV, Akeson MA, Kroog GS, Battey JF, and Jensen RT (1997) Effect of gastrin-releasing peptide receptor number on receptor affinity, coupling, degradation, and modulation. Mol Pharmacol 51:721-732. (Pubitemid 27224677)
43. Von Schrenck T, Heinz-Erian P, Moran T, Mantey SA, Gardner JD, and Jensen RT (1989) Neuromedin B receptor in esophagus: evidence for subtypes of bombesin receptors. Am J Physiol 256:G747-G758. (Pubitemid 19110558)
44. Wada E, Way J, Shapira H, Kusano K, Lebacq-Verheyden AM, Coy D, Jensen R and Battey J (1991) cDNA cloning, characterization, and brain region-specific expression of a neuromedin B-preferring bombesin receptor. Neuron 6:421-430.